Depending on a variety of factors, there are various options for the treatment of genitourinary cancers (included bladder, kidney, and prostate cancers) including immunotherapy. This guide, published by Patient Resource Publishing in partnership with the Society for Immunotherapy of Cancer (SITC...
2020_Immuno_GU.pdf
This is the library for the enduring materials from the Targets in Cancer IO: A Deep Dive, LAG 3 biology and Clinical Results webinar that took place on June 13, 2022. Moderators : Drew M. Pardoll, MD, PhD – Johns Hopkins University Dario A.A. Vignali, PhD – University of...
9 attachments
Presentation slides and video from the 2021-2022 Advances in Cancer Immunotherapy ™ Series - A Focus on Cellular Therapies and T Cell Engagers held virtually on December 18, 2021 are available here. Program Organizers Sairah Ahmed, MD – The University of Texas MD Anderson...
10 attachments
On October 13, 2021, leading experts from the SITC Immune Effector Cell-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Case Studies in Immune Effector Cell-related Adverse Events." This high-level webinar covered advanced concepts of...
2 attachments
On August 12, 2021, leading experts from the SITC Immune Effector Cell-related Adverse Events Guideline Expert Panel presented the "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immune Effector Cell-related Adverse Events." This high-level webinar covered advanced...
On Monday, June 21, 2021 from 4 – 5 pm ET, leading experts from the SITC Lymphoma Immunotherapy Guideline Expert Panel presented "SITC Clinical Practice Guideline Webinar – Practical Management Pearls for Immunotherapy for the Treatment of Lymphoma." This high-level webinar was designed so that...
On July 7, 2021, leading experts in cancer immunotherapy presented an advanced webinar focused on the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma." This high-level webinar was designed so that attendees will be able to...
On June 16, 2021, leading experts in cancer immunotherapy presented an advanced webinar focused on "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma." This high-level webinar was designed so that attendees will be able to...
On March 5, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" during a live webinar. The recorded webinar and presentation slides are...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric and adult patients in a number of disease states, as ‘living drugs,’ their toxicity...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us